Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $129,880.00 in Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 20th. The stock was sold at an average price of $32.47, for a total value of $129,880.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Thomas Gad also recently made the following trade(s):

  • On Tuesday, May 18th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $34.07, for a total value of $136,280.00.
  • On Monday, June 14th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $35.80, for a total value of $143,200.00.
  • On Friday, May 28th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $36.95, for a total value of $147,800.00.
  • On Monday, April 26th, Thomas Gad sold 7,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $27.96, for a total value of $195,720.00.

Shares of YMAB stock opened at $35.05 on Thursday. The company has a 50 day moving average of $34.42. Y-mAbs Therapeutics, Inc. has a twelve month low of $24.77 and a twelve month high of $55.22. The stock has a market cap of $1.53 billion, a P/E ratio of -22.32 and a beta of 1.20.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Thursday, May 6th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.61 by $0.14. The business had revenue of $5.38 million during the quarter, compared to analyst estimates of $35.67 million. Research analysts expect that Y-mAbs Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.

YMAB has been the topic of a number of research reports. Zacks Investment Research downgraded Y-mAbs Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 13th. HC Wainwright restated a “buy” rating and set a $68.00 price target on shares of Y-mAbs Therapeutics in a research note on Wednesday, July 7th. Bank of America upgraded Y-mAbs Therapeutics from a “neutral” rating to a “buy” rating in a research note on Friday, May 7th. Finally, Wedbush lowered their target price on Y-mAbs Therapeutics from $67.00 to $52.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 21st. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Y-mAbs Therapeutics currently has an average rating of “Buy” and an average target price of $54.13.

Several institutional investors and hedge funds have recently bought and sold shares of YMAB. First Light Asset Management LLC lifted its holdings in shares of Y-mAbs Therapeutics by 48.5% in the 1st quarter. First Light Asset Management LLC now owns 944,253 shares of the company’s stock valued at $28,554,000 after buying an additional 308,601 shares during the period. Ashford Capital Management Inc. lifted its holdings in shares of Y-mAbs Therapeutics by 131.6% in the 1st quarter. Ashford Capital Management Inc. now owns 508,083 shares of the company’s stock valued at $15,364,000 after buying an additional 288,664 shares during the period. Artisan Partners Limited Partnership lifted its holdings in shares of Y-mAbs Therapeutics by 25.8% in the 1st quarter. Artisan Partners Limited Partnership now owns 1,317,900 shares of the company’s stock valued at $39,853,000 after buying an additional 270,484 shares during the period. Oracle Investment Management Inc. lifted its holdings in shares of Y-mAbs Therapeutics by 201.3% in the 1st quarter. Oracle Investment Management Inc. now owns 380,642 shares of the company’s stock valued at $11,511,000 after buying an additional 254,300 shares during the period. Finally, Alliancebernstein L.P. lifted its holdings in shares of Y-mAbs Therapeutics by 21.9% in the 1st quarter. Alliancebernstein L.P. now owns 1,231,338 shares of the company’s stock valued at $37,236,000 after buying an additional 221,019 shares during the period. 60.77% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Featured Article: Why does the United States have a lingering trade deficit?

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.